HUMA Earnings Date: Nov 11, 2026 (Estimated) — Humacyte, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is HUMA's next earnings date?
Humacyte, Inc. (HUMA) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.09 on revenue of $766,000.
How did HUMA do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Humacyte, Inc. posted EPS of -$0.16 versus the -$0.11 estimate, a miss of 60.0%. Revenue was $406,000 against a $1.0M estimate. The stock's 1-day post-earnings move was -6.3%.
How much does HUMA stock move after earnings?
HUMA beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.1% (up or down) in the day after earnings.
About Humacyte, Inc.
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.11 | -0.16 | -60.00% | $406,000 | ❌ Miss | -6.34% | -18.07% | -20.13% |
| 2026-05-13 | Q1 2026 | -0.11 | -0.09 | +18.18% | $495,000 | ✅ Beat | +24.18% | -9.31% | +18.68% |
| 2026-03-27 | Q4 2025 | -0.13 | -0.13 | +0.00% | $467,000 | ➖ Inline | -13.21% | -17.47% | +3.53% |
| 2025-11-12 | Q3 2025 | -0.16 | -0.11 | +31.25% | $753,000 | ✅ Beat | -2.34% | -6.25% | +2.34% |
| 2025-08-11 | Q2 2025 | -0.17 | -0.24 | -41.18% | $301,000 | ❌ Miss | -29.64% | -24.19% | -39.52% |
| 2025-03-28 | Q4 2024 | -0.25 | -0.16 | +36.00% | $0 | ✅ Beat | -2.49% | -27.86% | -27.36% |
| 2024-11-08 | Q3 2024 | -0.25 | -0.33 | -32.00% | $0 | ❌ Miss | +9.89% | -7.98% | -19.87% |
| 2024-08-13 | Q2 2024 | -0.24 | -0.27 | -12.50% | $0 | ❌ Miss | +0.53% | -4.31% | -13.98% |
Showing last 8 quarters.